Regulation of arginine vasopressin in the human heart

Circulation Journal

Volumn 69, Issue 11, 2005, Pages 1401-1404

  Watanabe, Ikuyoshi ^a   Tani, Shigemasa ^a   Nagao, Ken ^a   Anazawa, Takeo ^a   Kawamata, Hirofumi ^a   Ohguchi, Sumito ^a   Kanmatsuse, Katsuo ^a   Kushiro, Toshio ^a  

^a SURUGADAI NIHON UNIVERSITY HOSPITAL   (Japan)

Author keywords

Arginine vasopression; Heart failure; Human heart

Indexed keywords

ARGIPRESSIN;

ADULT; AGED; ANGIOCARDIOGRAPHY; AORTA ROOT; ARTICLE; BLOOD SAMPLING; CORONARY SINUS; FEMALE; HEART; HEART FUNCTION; HEART STROKE VOLUME; HEART VENTRICULOGRAPHY; HORMONE SYNTHESIS; HUMAN; MAJOR CLINICAL STUDY; MALE; REGULATORY MECHANISM;

AGED; ARGININE VASOPRESSIN; CORONARY ANGIOGRAPHY; FEMALE; HUMANS; MALE; MIDDLE AGED; MYOCARDIAL INFARCTION; MYOCARDIUM; STROKE VOLUME;

EID: 27644437533     PISSN: 13469843     EISSN: 13474820     Source Type: Journal    
DOI: 10.1253/circj.69.1401     Document Type: Article

References (16)

1. Takeuchi I, Inomata T, Nishii M, Koitabashi T, Nakano H, Shinagawa H, et al. Clinical characteristics of heart disease patients with a good prognosis in spite of markedly increased plasma levels of type-B natriuretic peptide (BNP). Circ J 2005; 69: 277-282.
2. Nakagawa K, Umetani K, Fujioka D, Sano K, Nakamura T, Kodama Y, et al. Correlation of plasma concentrations of B-type natriuretic peptide with infarct size quantified by tomographic thallium-201 myocardial scintigraphy in asymptomatic patients with previous myocardial infarction. Circ J 2004; 68: 923-927.
3. Kjaer A, Hesse B. Heart failure and neuroendocrine activation: Diagnostic, prognostic and therapeutic perspectives. Clin Physiol 2001; 21: 661-672.
4. Gheorghiade M, Gattis WA, O'Connor CM, Adams KF Jr, Elkayam U, Barbagelata A, et al. Acute and Chronic Therapeutic Impact of a Vasopressin Antagonist in Congestive Heart Failure (ACTIV in CHF) Investigators: Effects of tolvaptan, a vasopressin antagonist, in patients hospitalized with worsening heart failure: A randomized controlled trial. JAMA 2004; 291: 1963-1971.
5. Gheorghiade M, Gattis WA, Barbagelata A, Adams KF Jr, Elkayam U, Orlandi C, et al. Acute and Chronic Therapeutic Impact of a Vasopressin Antagonist in Congestive Heart Failure Investigators: Rationale and study design for a multicenter, randomized, double-blind, placebo-controlled study of the effects of tolvaptan on the acute and chronic outcomes of patients hospitalized with worsening congestive heart failure. Am Heart J 2003; 145(Suppl 2): S51-S54.
6. Gheorghiade M, Niazi I, Ouyang J, Czerwiec F, Kambayashi J, Zampino M, et al. Tolvaptan Investigators: Vasopressin V2-receptor blockade with tolvaptan in patients with chronic heart failure: Results from a double-blind, randomized trial. Circulation 2003; 107: 2690-2696.
7. Udelson JE, Smith WB, Hendrix GH, Painchaud CA, Ghazzi M, Thomas I, et al. Acute hemodynamic effects of conivaptan, a dual V(1A) and V(2) vasopressin receptor antagonist, in patients with advanced heart failure. Circulation 2001; 104: 2417-2423.
8. Mukoyama M, Nakao K, Saito Y, Ogawa Y, Hosoda K, Suga S, et al. Increased human brain natriuretic peptide in congestive heart failure. N Engl J Med 1990; 323: 757-758.
9. Yasue H, Yoshimura M, Sumida H, Kikuta K, Kugiyama K, Jougasaki M, et al. Localization and mechanism of secretion of B-type natriuretic peptide in comparison with those of A-type natriuretic peptide in normal subjects and patients with heart failure. Circulation 1994; 90: 195-203.
10. Goldsmith SR, Francis GS, Cowley AW Jr, Levine TB, Cohn JN. Increased plasma arginine vasopressin levels in patients with congestive heart failure. J Am Coll Cardiol 1983; 16: 1385-1390.
11. Francis GS, Benedict C, Johnstone DE, Kirlin PC, Nicklas J, Liang CS, et al. Comparison of neuroendocrine activation in patients with left ventricular dysfunction with and without congestive heart failure: A substudy of the Studies of Left Ventricular Dysfunction (SOLVD). Circulation 1990; 82: 1724-1729.
12. Goldsmith SR, Francis GS, Cowley AW Jr, Levine TB, Cohn JN. Increased plasma arginine vasopressin levels in patients with congestive heart failure. J Am Coll Cardiol 1983; 1: 1385-1390.
13. Goldsmith SR, Francis GS, Cowley AW Jr. Arginine vasopressin and the renal response to water loading in congestive heart failure. Am J Cardiol 1986; 58: 295-299.
14. Wada K, Fujimori A, Matsukawa U, Arai Y, Sudoh K, Yatsu T, et al. Intravenous administration of conivaptan hydrochloride improves cardiac hemodynamics in rats with myocardial infarction-induced congestive heart failure. Eur J Pharmacol 2005; 507: 145-151.
15. Hupf H, Grimm D, Riegger G, Schunkert H. Evidence for a vasopressin system in the rat heart. Circ Res 1999; 84: 365-370.
16. Chandrashekhar Y, Prahash AJ, Sen S, Gupta S, Roy S, Anand IS. The role of arginin vasopressin and its receptors in the normal and failing rat heart. J Mol Cell Cardiol 2003; 35: 495-505.